13951-70-7

  • Product Name:11a,16b,17,21-Tetrahydroxy-pregna-1,4-diene-3,20-dione
  • Molecular Formula:C21H28O6
  • Purity:99%
  • Molecular Weight:376.45
Inquiry

Product Details;

CasNo: 13951-70-7

Molecular Formula: C21H28O6

Appearance: white crystalline solid

Wholesale 11a,16b,17,21-Tetrahydroxy-pregna-1,4-diene-3,20-dione 13951-70-7 Efficient Shipping Low Price

  • Molecular Formula:C21H28O6
  • Molecular Weight:376.45
  • Appearance/Colour:white crystalline solid 
  • Vapor Pressure:1.86E-16mmHg at 25°C 
  • Melting Point:235-238 °C 
  • Refractive Index:1.629 
  • Boiling Point:591.5 °C at 760 mmHg 
  • PKA:11.93±0.70(Predicted) 
  • Flash Point:325.6 °C 
  • PSA:115.06000 
  • Density:1.381 g/cm3 
  • LogP:0.52840 

11a,16b,17,21-Tetrahydroxy-pregna-1,4-diene-3,20-dione(Cas 13951-70-7) Usage

Chemical Properties

11α,16β,17,21-Tetrahydroxy-pregna-1,4-diene-3,20-dione, also known as 16α-hydroxyprednisolone, is a steroid compound with a complex molecular structure. It is characterized by the presence of four hydroxy (-OH) groups at specific positions on the steroid nucleus, along with double bonds at positions 1 and 4, and ketone groups at positions 3 and 20.

Uses

Pharmaceutical Applications: 11α,16β,17,21-Tetrahydroxy-pregna-1,4-diene-3,20-dione finds extensive use in the pharmaceutical industry, particularly in the synthesis of corticosteroids and related medications. It serves as a key intermediate in the production of various corticosteroid drugs used for their anti-inflammatory, immunosuppressive, and metabolic effects.

Anti-inflammatory Medications: This compound, also known as 16α-hydroxyprednisolone, is utilized in the synthesis of medications with potent anti-inflammatory properties. These medications are often prescribed for the treatment of inflammatory conditions such as arthritis, asthma, dermatitis, and allergic reactions.

Immunosuppressive Agents: Certain corticosteroid drugs derived from 11α,16β,17,21-Tetrahydroxy-pregna-1,4-diene-3,20-dione are employed as immunosuppressive agents in the management of autoimmune disorders and to prevent organ rejection in transplant recipients.

Dermatological Treatments: Some formulations containing corticosteroids synthesized from this compound are utilized topically in dermatology for the treatment of various skin conditions, including eczema, psoriasis, and allergic dermatitis.

Research: In addition to its pharmaceutical applications, 11α,16β,17,21-Tetrahydroxy-pregna-1,4-diene-3,20-dione is also used as a research tool in studies investigating the mechanisms of action of corticosteroids and their potential therapeutic applications in various disease states.

InChI:InChI=1/C21H28O6/c1-19-6-5-12(23)7-11(19)3-4-13-14-8-16(25)21(27,17(26)10-22)20(14,2)9-15(24)18(13)19/h5-7,13-16,18,22,24-25,27H,3-4,8-10H2,1-2H3

13951-70-7 Relevant articles

Preparation method and application of 16, 17-dihydroxy steroid compound

-

, (2022/01/08)

The invention provides a preparation met...

Method for preparing 16 alpha-hydroxyprednisolone

-

, (2020/07/02)

The invention discloses a method for pre...

Preparation method of high-purity 16 alpha-hydroxyprednisolone

-

Paragraph 0026-0040, (2021/01/04)

The invention discloses a preparation me...

9-site dehalogenation method of steroid compound

-

Paragraph 0020, (2020/05/01)

The invention discloses a 9-site dehalog...

13951-70-7 Process route

11β,16α,17α,21-tetrahydroxypregnane-1,4-diene-3,20-dione-21-acetate
86401-80-1

11β,16α,17α,21-tetrahydroxypregnane-1,4-diene-3,20-dione-21-acetate

desonide
13951-70-7

desonide

Conditions
Conditions Yield
With sodium hydroxide; In methanol; dichloromethane; at 0 - 5 ℃; for 1h; Inert atmosphere;
93.5%
With sodium hydroxide; In methanol; at 20 ℃; for 2h;
91.1%
In toluene; at 40 - 45 ℃; Solvent;
78.9%
With sodium sulfite; In methanol; dichloromethane; water; at 0 ℃; Reagent/catalyst;
73%
With methanol; potassium hydroxide; In ethanol; dichloromethane; at -10 ℃; Reagent/catalyst; Temperature;
36 mg
16α-21-diacetoxyprednisolone
98422-55-0

16α-21-diacetoxyprednisolone

desonide
13951-70-7

desonide

Conditions
Conditions Yield
In toluene; at 40 - 45 ℃; Solvent;
70.5%
In toluene; at 40 - 45 ℃; Solvent;
70.5%
In toluene; at 40 - 45 ℃; Solvent;
70.5%
With solid phase base catalyst; In toluene; at 40 - 45 ℃;
 
With solid phase alkali catalyst; In toluene; at 40 - 45 ℃; Solvent; Reagent/catalyst;
70.5 g

13951-70-7 Upstream products

  • 1171-81-9
    1171-81-9

    11β,16α,17,21-tetrahydroxy-pregn-4-ene-3,20-dione

  • 37413-91-5
    37413-91-5

    2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

  • 77017-20-0
    77017-20-0

    16α,17α,21-trihydroxypregna-1,4,9(11)-triene-3,20-dione-21-acetate

  • 91160-89-3
    91160-89-3

    9α-bromo-11β,16α,17α,21-tetrahydroxypregnane-1,4-diene-3,20-dione-21-acetate

13951-70-7 Downstream products

  • 638-94-8
    638-94-8

    desonide

  • 124-94-7
    124-94-7

    triamcinolone

  • 22199-85-5
    22199-85-5

    16α,21-diacetoxy-9-chloro-11β,17-dihydroxy-pregna-1,4-diene-3,20-dione

  • 1868-22-0
    1868-22-0

    16α,21-diacetoxy-9-fluoro-17-hydroxy-pregna-1,4-diene-3,11,20-trione

Relevant Products